# MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck

> **NCT00427102** · PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Squamous Cell Carcinoma
- Head and Neck Cancer
- Resected Head and Neck Cancer
- Mucositis

## Interventions

- **DRUG:** Oral MRX-1024
- **PROCEDURE:** Standard Fractionation Radiation Therapy
- **DRUG:** High-Dose Cisplatin Chemotherapy

## Key facts

- **NCT ID:** NCT00427102
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** — (—)
- **Why stopped:** No subjects enrolled and PI went to another facility
- **Last updated:** 2012-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427102, "MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00427102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*